Does Wegovy Lead to Significant Weight Loss?
Wegovy (semaglutide) produces average weight loss of 15-17% of body weight over 68 weeks in adults with obesity or overweight with comorbidities, compared to 2-3% with placebo. In clinical trials like STEP 1, participants on 2.4 mg weekly lost 14.9% on average versus 2.4% on placebo.[1][2] Real-world data shows similar results, with sustained loss when combined with diet and exercise.
How Much Weight Can You Expect to Lose?
Loss varies by dose, duration, and adherence:
- At 0.25-1.7 mg doses (titration phase): 5-10% over 16-20 weeks.
- Full 2.4 mg dose: Up to 17.4% in STEP 5 trial over 104 weeks.[3]
- Adolescents (12+): 16.1% average in a 2022 trial.[4]
Men and women lose comparably, but those with higher baseline BMI see greater absolute loss.
How Does Wegovy Compare to Other Weight Loss Drugs?
| Drug | Active Ingredient | Avg. Weight Loss (68 weeks) | Key Difference |
|------|-------------------|-----------------------------|---------------|
| Wegovy | Semaglutide | 15-17% | Highest efficacy; weekly injection |
| Ozempic | Semaglutide (lower dose) | 10-12% | Same drug family; diabetes-focused |
| Zepbound | Tirzepatide | 20-22% | Dual GLP-1/GIP; slightly more effective[5] |
| Saxenda | Liraglutide | 5-8% | Daily injection; less potent |
| Phentermine | Various | 5-10% (short-term) | Oral; appetite suppressant only |
Wegovy outperforms older GLP-1 drugs like Saxenda but trails dual-agonists like Zepbound in head-to-head potential.
What Do Clinical Trials Show Long-Term?
STEP trials (FDA basis for approval):
- STEP 1: 83% of Wegovy users lost ≥5% body weight vs. 31% placebo.[1]
- STEP 4: 10.6% additional loss after 48 weeks vs. regain on placebo.[6]
Loss plateaus after year 1 but holds with continued use; discontinuation leads to ~2/3 regain within a year.[7]
Why Does Wegovy Work for Weight Loss?
It mimics GLP-1 hormone, slowing gastric emptying, reducing appetite, and signaling fullness to the brain. fMRI studies show decreased reward response to high-calorie foods.[8] Not just caloric restriction—alters hunger signaling for better adherence.
What If You Stop Taking Wegovy?
Most regain 12-15% of lost weight within 12 months post-discontinuation, per STEP 1 extension data. Lifestyle changes mitigate some regain, but drug is needed for maintenance in trials.[7]
Common Side Effects and Risks
GI issues (nausea 44%, diarrhea 30%, vomiting 24%) peak early and fade.[1] Rare risks: Pancreatitis, gallbladder disease (4%), thyroid tumors (black-box warning from rodent data). Not for those with medullary thyroid cancer history. Heart benefits in trials: 20% lower CV events.[9]
Who Gets the Best Results?
- Responders: 50-60% lose ≥15%; early response (5% loss by week 12) predicts success.[10]
- Poor responders: Tied to lower adherence or genetics.
- Not for everyone: BMI ≥30 or ≥27 with conditions like hypertension.
Cost and Access Issues
$1,300-$1,700/month without insurance; coupons or GLP-1 savings cards cut to $0-$500 for eligible.[11] Shortages persist since 2023.
[1]: NEJM, STEP 1 Trial (2021) - https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[2]: Novo Nordisk prescribing info - https://www.wegovy.com
[3]: NEJM, STEP 5 (2022) - https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[4]: NEJM, Adolescent Trial (2022) - https://www.nejm.org/doi/full/10.1056/NEJMoa2202785
[5]: NEJM, SURMOUNT-1 (Zepbound) - https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[6]: NEJM, STEP 4 (2021) - https://www.nejm.org/doi/full/10.1056/NEJMoa2107285
[7]: Wilding et al., Diabetes Care (2022)
[8]: Farooqi et al., Nature (2021)
[9]: SELECT Trial, NEJM (2023) - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
[10]: Garvey et al., Obesity (2022)
[11]: Novo Nordisk patient assistance - https://www.novocare.com